By Sam Boughedda
Investing.com -- Moderna Inc (NASDAQ: MRNA ) has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine, the company said Monday.
Moderna shares rose 17% after the announcement.
Moderna explained in a press release that the open-label, multicenter, randomized Phase 1 trial is designed to assess the safety and immunogenicity of experimental HIV trimer mRNA vaccines.
The company's idea is that the trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will produce neutralizing antibodies.
The trial, sponsored and funded by the Division of AIDS of the National Institute of Allergy and Infectious Diseases within the National Institutes of Health, will enroll approximately 100 HIV-negative adults aged 18 to 55 years.
"Developing a vaccine regimen that induces sustained protective levels of HIV neutralizing antibodies in humans has been difficult to achieve. At Moderna, we believe that mRNA offers an opportunity to take a fresh approach to this challenge," said Stephen Hoge, president of Moderna.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.